Through their interaction with the TNF receptor–associated factor (TRAF) family, members of the tumor necrosis factor receptor (TNFR) superfamily elicit a wide range of biological effects including differentiation, proliferation, activation, or cell death. We have identified and characterized a novel component of the receptor–TRAF signaling complex, designated TRIP (TRAF-interacting protein), which contains a RING finger motif and an extended coiled-coil domain. TRIP associates with the TNFR2 or CD30 signaling complex through its interaction with TRAF proteins. When associated, TRIP inhibits the TRAF2-mediated NF-κB activation that is required for cell activation and also for protection against apoptosis. Thus, TRIP acts as a receptor–proximal regulator that may influence signals responsible for cell activation/proliferation and cell death induced by members of the TNFR superfamily.
TRAF-interacting Protein (TRIP): A Novel Component of the Tumor Necrosis Factor Receptor (TNFR)- and CD30-TRAF Signaling Complexes That Inhibits TRAF2-mediated NF-κB Activation
Address correspondence to Dr. Yongwon Choi, HHMI, The Rockefeller University, 1230 York Ave., Box 295, New York, NY 10021.
Y. Choi, is an assistant investigator of the Howard Hughes Medical Institute.
1Abbreviations used in this paper: β-gal; β-galactosidase; c-IAP, cellular inhibitors of apoptosis protein; GST, glutathione-S-transferase; h, human; IL-1R, IL-1 receptor; m, mouse; TNFR, TNF receptor; TRAF, TNFRassociated factor; TRIP, TRAF-interacting protein.
Soo Young Lee, Sang Yull Lee, Yongwon Choi; TRAF-interacting Protein (TRIP): A Novel Component of the Tumor Necrosis Factor Receptor (TNFR)- and CD30-TRAF Signaling Complexes That Inhibits TRAF2-mediated NF-κB Activation. J Exp Med 7 April 1997; 185 (7): 1275–1286. doi: https://doi.org/10.1084/jem.185.7.1275
Download citation file:
Sign in
Client Account
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement